PR Newswire
LAS VEGAS, Jan. 29, 2026
The chronic hepatitis D virus market is expected to grow steadily, driven by a relatively small pipeline of emerging therapies. Leading candidates, such as Brelovitug from Bluejay Therapeutics and the Tobevibart + Elebsiran combination from Vir Biotechnology, highlight the industry’s growing focus on this high unmet need, as developers continue to advance innovative treatment approaches for this challenging disease.
LAS VEGAS, Jan. 29, 2026 /PRNewswire/ — DelveInsight’s Chronic Hepatitis D Market Insights report includes a comprehensive understanding of current treatment practices, chronic hepatitis D emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).
https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
Chronic Hepatitis D Market Summary
- The market size for chronic hepatitis D in the leading markets is expected to grow significantly by 2034.
- The United States accounted for the highest chronic hepatitis D treatment market size in 7MM in 2024, in comparison to the other major markets, i.e., EU4 countries, the United Kingdom, and Japan.
- Over 12 million people globally are chronically infected with the hepatitis D virus, which is recognized as the most severe form of viral hepatitis.
- Leading chronic hepatitis D companies developing emerging therapies, such as Bluejay Therapeutics, Vir Biotechnology, and others, are developing new therapy for chronic hepatitis D that can be available in the chronic hepatitis D market in the coming years.
- The promising chronic hepatitis D therapies in clinical trials include Brelovitug (BJT-778), Tobevibart + Elebsiran, and others.
Discover the opportunities and challenges in the hepatitis D market @ https://www.delveinsight.com/sample-request/chronic-hepatitis-delta-virus-infection-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr
Key Factors Driving the Growth of the Chronic Hepatitis D Market
- Rising Global Disease Burden: Increased prevalence of HDV infection, especially in regions with high hepatitis B (HBV) incidence, such as parts of Africa, the Mediterranean, Eastern Europe, and Asia-Pacific.
- Growing Awareness and Diagnosis: Improved screening and diagnostic capabilities are enabling earlier and more accurate detection of HDV in HBV-infected patients.
- Multi-Targeted Strategies in HDV Management: Brelovitug from Bluejay Therapeutics, along with Tobevibart plus Elebsiran from Vir Biotechnology, are emerging as promising next-generation treatments for chronic HDV. By addressing viral entry and replication through complementary approaches, these therapies signal a shift toward multi-targeted strategies that may offer greater effectiveness than traditional interferon-based treatments.
Chronic Hepatitis D Market Analysis
- Testing for the hepatitis D virus remains limited despite its clinical importance. Lack of standardized HDV RNA assays hampers accurate detection of active infection and monitoring of treatment response. This contributes to underdiagnosis and delays in timely clinical management.
- Pegylated interferon alpha (PEG-IFNα) was historically the only available therapy for chronic HDV.
- Clinical utility is limited due to modest efficacy, high rates of side effects, and multiple contraindications. Few patients achieve a complete virological response, and relapses are common after treatment ends.
- The treatment landscape is evolving, with new therapies showing promising outcomes. In 2023, bulevirtide, a once-daily subcutaneous entry inhibitor, was approved by the European Medicines Agency for adults with chronic HDV.
- Ongoing multicenter studies are evaluating optimal dosing, treatment duration, and potential combination strategies with PEG-IFNα.
- Nucleoside analogues used for hepatitis B management show no direct antiviral effect on HDV. They remain important for controlling concurrent HBV infection in co-infected patients.
To know more about what is the impact of new therapies on market growth, visit @ Approved Chronic Hepatitis D Drugs
Chronic Hepatitis D Competitive Landscape
Brelovitug (Bluejay Therapeutics) and the Tobevibart + Elebsiran (Vir Biotechnology) represent promising next-generation therapies for chronic HDV. Targeting viral entry and replication through complementary mechanisms, they reflect a shift toward multi-targeted, more effective treatment strategies beyond interferon-based options.
Bluejay Therapeutics’ Brelovitug (BJT-778) is a highly potent, fully human IgG1 monoclonal antibody that specifically targets the hepatitis B virus surface antigen (anti-HBsAg) and exhibits pan-genotypic activity. It is under investigation as a potential standalone therapy for adults with chronic hepatitis D and as a cornerstone of combination strategies aimed at achieving a functional cure for chronic hepatitis B. Brelovitug works by neutralizing and clearing hepatitis B and D virions and depleting HBsAg-containing subviral particles. Additionally, it has demonstrated potential as a powerful immunomodulator.
Tobevibart is an investigational monoclonal antibody administered subcutaneously that targets the hepatitis B surface antigen to prevent hepatitis B and D viruses from entering liver cells while reducing circulating viral particles. It incorporates extended half-life technologies and is being clinically evaluated for chronic hepatitis B and D.
Elebsiran is a subcutaneous investigational siRNA therapy designed to degrade hepatitis B virus RNA, thereby reducing surface antigen production. It has shown potential antiviral activity against both hepatitis B and D viruses and is being developed through a collaboration between Vir Biotechnology and Alnylam Pharmaceuticals.
The anticipated launch of these emerging therapies are poised to transform the chronic hepatitis D market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the chronic hepatitis D market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about what are the leading HDV treatments and pipeline therapies @ Chronic Hepatitis D Clinical Trials
What is Chronic Hepatitis D?
Chronic hepatitis D (CHD) is a severe, progressive liver disease caused by persistent infection with the hepatitis D virus (HDV), a defective RNA virus that can only replicate in the presence of the hepatitis B virus (HBV). It occurs either as a coinfection with HBV or, more commonly in chronic cases, as a superinfection in individuals already living with chronic hepatitis B. CHD is considered the most aggressive form of viral hepatitis, characterized by faster disease progression and a significantly higher risk of advanced liver complications, including cirrhosis, hepatic decompensation, and hepatocellular carcinoma. Despite affecting a relatively smaller patient population compared with other viral hepatitides, chronic hepatitis D represents a major unmet medical need due to limited therapeutic options and historically poor clinical outcomes.
Chronic Hepatitis D Epidemiology Segmentation
The chronic hepatitis D epidemiology section provides insights into the historical and current chronic hepatitis D patient pool and forecasted trends for the leading markets. In the US, up to 2.4 million people are hepatitis B surface antigen (HBsAg)-positive. Among them, 3-6% test positive for HDV antibodies, and 50-70% of those have active HDV infection based on RNA testing, translating to an estimated 70,000 to 150,000 active HDV cases in the US.
The chronic hepatitis D market report proffers epidemiological analysis for the study period 2020-2034 in the leading markets, segmented into:
- Total Prevalent Cases of Chronic Hepatitis D Virus
- Total Diagnosed Prevalent Cases of Chronic Hepatitis D Virus
- Gender-specific Cases of Chronic Hepatitis D Virus
- Age-specific Cases of Chronic Hepatitis D Virus
- Treated Cases of Chronic Hepatitis D Virus
Chronic Hepatitis D Market Report Metrics
Details
Study Period
2020-2034
Chronic Hepatitis D Market Report Coverage 7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and
Japan].
Chronic Hepatitis D Epidemiology Total Prevalent Cases of Chronic Hepatitis D Virus, Total Diagnosed Prevalent Cases of Chronic
Segmentation Hepatitis D Virus, Gender-specific Cases of Chronic Hepatitis D Virus, Age-specific Cases of
Chronic Hepatitis D Virus, and Treated Cases of Chronic Hepatitis D Virus
Key Chronic Hepatitis D Companies
Bluejay Therapeutics, Vir Biotechnology, Gilead Sciences, and others
Key Chronic Hepatitis D Therapies
Brelovitug (BJT-778), Tobevibart + Elebsiran, HEPCLUDEX, and others
Scope of the
Chronic Hepatitis D
Market Report
- Therapeutic Assessment: Chronic Hepatitis D current marketed and emerging therapies
- Chronic Hepatitis D Market Dynamics: Key Market Forecast Assumptions of Emerging Chronic Hepatitis D Drugs and Market Outlook
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Chronic Hepatitis D Market Access and Reimbursement
Download the report to understand can hepatitis B vaccination prevent hepatitis D @ Chronic Hepatitis D Vaccine
Table of Contents
1
Chronic Hepatitis D Market Key Insights
2
Chronic Hepatitis D Market Report Introduction
3
Chronic Hepatitis D Market Overview at a Glance
3.1. Chronic Hepatitis D Market Share (%) Distribution by
Therapies in 2024
3.2. Chronic Hepatitis D Market Share (%) Distribution by
Therapies in 2034
4
Epidemiology and Market Methodology
5
Executive Summary
6
Key Events
7
Disease Background and Overview
7.1.
Introduction
7.2
Types
7.3.
Causes
7.4.
Pathophysiology
7.5.
Symptoms
7.6.
Risk Factor
7.7.
Diagnosis
7.8.
Treatment and Management
8
Epidemiology and Patient Population
8.1
Key Findings
8.2
Assumptions and Rationale: The 7MM
8.3 Total Prevalent Cases of Chronic Hepatitis D Virus in the
7MM
8.4 Total Diagnosed Prevalent Cases of Chronic Hepatitis D
Virus in the 7MM
8.5
The US
8.5.1 Total Prevalent Cases of Chronic Hepatitis D Virus
8.5.2 Total Diagnosed Prevalent Cases of Chronic Hepatitis D
Virus
8.5.3 Gender-specific Cases of Chronic Hepatitis D Virus
8.5.4
Age-specific Cases of Chronic Hepatitis D Virus
8.5.5
Treated Cases of Chronic Hepatitis D Virus
8.6
EU4 and the UK
8.7
Japan
9
Chronic Hepatitis D Patient Journey
10
Marketed Chronic Hepatitis D Therapies
10.1
Key Cross Competition
10.2
HEPCLUDEX (Bulevirtide): Gilead Sciences
10.2.1
Drug Description
10.2.2
Regulatory Milestones
10.2.3
Other Development Activities
10.2.4
Clinical Trials Information
10.2.5
Safety and Efficacy
To be continued in the report….
11
Emerging Chronic Hepatitis D Therapies
11.1
Key Cross Competition
11.2
Brelovitug (BJT-778): Bluejay Therapeutics
11.2.1
Drug Description
11.2.2
Other Development Activities
11.2.3
Clinical Trials Information
11.2.4
Safety and Efficacy
11.2.5
Analysts’ Views
11.3
Tobevibart + Elebsiran: Vir Biotechnology
To be continued in the report….
12 Chronic Hepatitis D Virus Market: Seven Major Market
Analysis
12.1
Key Findings
12.2 Key Chronic Hepatitis D Market Forecast Assumptions
12.3
Chronic Hepatitis D Market Outlook
12.4
Attribute Analysis
12.5 Total Market Size of Chronic Hepatitis D Virus in the 7MM
12.6 Market Size of Chronic Hepatitis D Virus by Therapies in
the 7MM
12.7
The US Chronic Hepatitis D Market Size
12.7.1
Total Market Size of Chronic Hepatitis D Virus
12.7.2 Market Size of Chronic Hepatitis D Virus by Therapies
12.8
EU4 and the UK Chronic Hepatitis D Market Size
12.9.
Japan Chronic Hepatitis D Market Size
13 Key Opinion Leaders’ Views on Chronic Hepatitis D
14
Chronic Hepatitis D Market Unmet Needs
15
Chronic Hepatitis D Market SWOT Analysis
16 Chronic Hepatitis D Virus Market Access and Reimbursement
16.1
United States
16.2
EU4 and the UK
16.3
Japan
17
Bibliography
18
Abbreviations and Acronyms
19
Chronic Hepatitis D Market Report Methodology
Related Reports
Chronic Hepatitis D Clinical Trial Analysis
Chronic Hepatitis D Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key CHD companies, including Eiger BioPharmaceuticals, Huahui Health, Vir Biotechnology, Shanghai HEP Pharmaceutical, Janssen Research & Development, Bluejay Therapeutics, Assembly Biosciences, among others.
Chronic Hepatitis B Market
Chronic Hepatitis B Market Insights, Epidemiology, and Market Forecast
– 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CHB companies, including Vedanta Biosciences, Gilead Sciences, Dong-A ST Co, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech Limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharm, among others.
Hepatitis A Market
Hepatitis A Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hepatitis A companies, including Boryung Pharmaceutical, Cadila Healthcare, Indian Immunologicals, Biological E Limited, among others.
Hepatitis C Market
Hepatitis C Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hepatitis C companies, including AbbVie, Gilead Sciences, Atea Pharmaceuticals, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact UsShruti Thakur [email protected] +14699457679www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/chronic-hepatitis-d-market-poised-for-significant-growth-during-the-forecast-period-20252034-as-emerging-therapies-drive-optimism–delveinsight-302673537.html
Tengo varias preguntas sobre esto a ver si me podiais aclarar:
-¿Puedo hacer un ingreso regular de 800 euros y me cobran 0euos de comisiones y mto.?
-¿Puedo sacar el dinero cuando quiera?,¿todo ó tengo entendido que hay que mantener un mínimo de 100 euros los 30 meses?
-No necesito pero me obligan a sacar una tarjeta de débito que me cuesta 11 euros el primer año y 22 euros la renovación, también otra de credito que me cuesta 0 euros el primer año y 35 euros la renovación.
¿Hay que mantenerlas 13 meses?
¿Puedo cancelar alguna de ellas desde el principio?
¿Puedo cancelar alguna de ellas antes de la renovación?
¿Hay alguna tarjeta de credito más barata?
Aparte de la cuenta nómina he visto que también que para que te den la tv también se puede sacar una cuenta tarifa plana básica o personal, ¿sabeis algo de estas cuentas?¿que requisitos tienen?
Muchas gracias a todos por responder
Yo fui a informarme y te cuento. Únicamente admiten los ingresos regulares en el caso de que seas autónomo. Te abren una cuenta Tarifa Plana Cero que está exenta de comisiones y presenta alguna ventaja más. Sobre dejar un mínimo de saldo en la cuenta no es necesario, pero sí te obligan a mantener varias tarjetas durante los 30 meses con un coste aproximado de 100 euros anuales.
hola buenas!
me llamo javi y estoy dudando de que banco, me puede dar mas beficios, sin sorpresas por domiciliar la nomina, ya que llevo años en la caixa y no me da nada ningun beneficio. es mas me rechazan los prestamos que solicito, ni siquiera una targeta de credito, por alegan de que siempre esta a cero la cuenta, yo cuando cobro la nomina dejo el dinero para los pagos, y saco el resto, pues no me fio, de que un dia me quede sin dinero, ya que esta todo muy mal, corre riesgo mi dinero o mis ahorros en el banco?? muchas gracias y un cordial saludo.
javi
NO TE EXTRAÑE QUE NO TE DEN LOS PTMOS, PORQUE LO QUE VEN ES QUE NO TIENES CAPACIDAD DE AHORRO PORQUE SIEMPRE DEJAS LA CTA. EN MINIMOS, ASI NINGUN BANCO TE LO VA A CONCEDER. TAMBIEN ES VERDAD QUE LA CAIXA, COMO TANTAS OTRAS CAJAS, TIENE EL PUÑO CERRADO PARA LOS RIESGOS, PARA REMONTAR. NO TE PREOCUPES, QUE POR UNA NOMINA NO CREO QUE NINGUN BANCO SE COJA LAS MANOS. LOS QUE SE TIENEN QUE PREOCUPAR SON LOS QUE TIENEN DÉPÓSITOS Y FONDOS EN BANCOS DE DUDOSA ACTIVIDAD. LA GENTE SE PIENSA QUE PORQUE LES DEN UN 7% YA ES UN GRAN BANCO Y SE EQUIVOCAN. LO QUE LES PASA ES QUE EL BANCO DE ESPAÑA LES PRESTA EL DINERO MAS CARO Y POR ESO OPTAN POR CONSEGUIRLO EN EL MERCADO MONETARIO, Y SI EL BANCO DE ESPAÑA NO SE FIA DE ELLOS, VA Y SE FIA LA GENTE. QUE LOS BANCOS NOES LA ADMON PUBLICA, ABRAN OS OJOS.
Hola , cuando vallais al banco queos dejen lo que hay que pagar de irpf y de iva sobre el valor de la tele ya que en la mayoria de bancos esto no lo dicen y luego llagan las sorpresas .A mi ya me ha pasado con la promoción del portatil y nunca me hablaros de esto . Cuidado
Yo he estado calculando y la tele entre unas cosas y otras te sale sobre unos 250euros que tampoco regalan tanto .Hay oficinas en las que han dado la occión de poner un dinero a plazo fijo a 12meses de 9300euros o 6800euros a 18 meses.
No es ningún chollo. Te obligan a contratar dos tarjetas de crédito que tienes que pagar porque las tienes que mantener 13 meses por lo menos y además llevan unos costes desproporcionados si las utilizas. En total, no usando las tarjetas y anulándolas una vez cumplidos los 13 meses puedes ahorrar unos 38 euros con respecto al precio de ese televisor en una gran superficie. Y además luego vendrá que te cobran para hacienda la retención correspondiente, por lo que probablemente incluso en las mejores condiciones te cueste más que si ahorras un poco y lña compras directamente.
Creó que teneis toda la razón, que aqui no te regalan nada, ya que a mí me paso con unas sartenes que regalaban el banco bilbao, que al final entre el irpf y el descuento de Hacienda, al final me salieron caras, así es que no os tomen el pelo, que al final siempre esta la letra pequeña que es la que nos joroba, por no decir otra cosa.
Yo saque el portatil y ahora me he sacado la TV LCD 32. Estas promos no hay que declararlas. No es obligado domiciliar nomina. Si, meter en la cuenta 800€ todos los meses en un margen de 10 dias. Cero matacero, pero cero,cero, cero de gastos de mantenimiento, ni por recibos, ni por el correo a casa, ni por transfer. Las tarjets gratis el 1er año. Resto fuera. Dadas de baja Menos la de debito. Banesto no pierde nada, ganar, gana clientes que es el proposito de esta promo. Precio de portatil y tv 32 en mercao unos 900€ los 2. En banest 197€. Los hay mejores, nos ha jodio! portatiles a 1200€, TV LCD 32 a 1000€. Señores, son lentejas. Relacion calida-precio-promo es cojonud…….Un saludit a los viandantes.
hola , no se si llegara mi comentario pero os voi a esplicar. esto es el cuento de la abuela. mira yo tengo el portatil. y he cogio tab la tele, pero sabeis ke?, me ha pasado de todo. os esplico. primero me cobran 74 euros y 25 euros de unas tarjetas que yo no las he visto aparecer por mi casa , me cabreo con el banco. llamo y pido esplicaciones. me dicen que van en la promocion, nunca jamas nadie me informo de las tarjetas, no me devuelven el dinero. me cabreo y me dicen que llame aun numero de tefono para darlas de baja, se pasan los dias, intentamos darlas de baja. largas y larga, que si este numero de tefono que si el otro bla bla bla. conseguimos hablar y nos dicen que tenemos que cambiar el contrato a tarifa plana o no se ke historias, llamando al banco se pasan los dias, largas y largas. me cabreo y estoi por suspender todo, me dicen que si lo quiero cambiar y dar de baja las tarjetas que nunca he tenido. tengo que pagar comisiones cada seis meses de doce y pico euros, y que si no quiero que me cobren comisiones tengo que ir todos los meses al banco a hacerlo yo, ufffffffffff.aun hay mas. me dan de baja y me hacen la tarifa plana, se equivocan un monton de veces. me hacen pasar muchos cabreos.y al final cuando llego a casa me han cobrado 25, 50 euros. y llamo por telefono y se lo digo , me dicen claro por dar de baja la otra cuenta , la madre que los pario. ladrones. o sea os digo que la tele no sale regalada, se la cobran y muy bien cobrada , nadie da nada por nada. en cuento termine de pagar lo que debo quito todas las cuentas del banesto.espero que alguien me lea y que me conteste gracias .
Banesto ha jodido a mi marido y a un amigo tambien. Para mi, despues de Banco de Andalucía son los peores. Y quieran creerlo o no ni la television ni el portátil te lo regalan.. como no cumplas cualquiera de las reglas te sancionan con 300 y pico de euros.. porque nos hemos mudado de casa y los recibos domiciados se cortaron «temporalmente» la sancion fue de mas de 300 euros.. y el cabreo q te llevas cuando ves lo q te han descontado y luego para ir a reclamarlos.. y como te tratan !! en fin.. espero que Banesto sea lo primero en undirse en el fin del mundo!!
CHOLLO!!!!!!!!!JAJAJAJAJA…….NO ES NINGUN CHOLLO!!!!!!! te cobran 100 € de gastos de manipulacion, mas 150 € en tarjetas durante 2 años, mas 6 € mensuales de mantenimiento de cuenta durante 30 meses, total que pagas 630 Euros por un ordenador o una TV que su valor seguro que no llega a 500 €. Y encima si vas a cancelar la cuenta cuando cumples los 30 meses requeridos te hacen esperar dos horas para decirte que no tienen linea de telefono para dar de baja la cuenta, cosa que no para nunca cuando vas a contratarlo. Y del trato que dispensan….., es el mismo que si vas con un fajo de billetes de 500 € por los CO-JONES
Banesto «premia», menuda falacia…
No hay ningún banco que premie a nadie.
BANESTO NECESITA NUESTRAS NÓMINAS, Y EN CUANTO VAS UN POCO JUSTO, COMO BUENOS JUDÍOS Y ÁVAROS QUE SON, TE ACOSAN Y MACHACAN, Y TE SACAN HASTA LAS ENTRAÑAS EN COMISIONES.
DESPUÉS EL ESTADO APOYA A LOS BANCOS, CON LA EXCUSA DE QUE SI CAEN LOS BANCOS CAEMOS TODOS. LOS BANCOS NECESITAN UN BOICOT DE VEZ EN CUANDO, PARA QUE NO NOS RESTREGUEN POR LA CARA SUS BENEFICIOS.
POR CIERTO, LO QUE MÁS FASTIDIA A UN BANCO ES UNA RECLAMACIÓN EN LA OFICINA DEL CONSUMIDOR Y OTRA AL BANCO DE ESPAÑA.
ES POR DAR PISTAS…